Our Gene Transfer Platform
Targeted, Flexible, Efficient
Our Zip-Code™ Technology platform is a first in class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ are derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.
Groundbreaking, Pioneering, Ushering in a New Era of Gene Therapies
Our science is redefining the boundaries of medicine, fueling new therapeutic approaches and providing a diversity of tools to oncologists and hope to families and patients with cancer.
About Us: Team and Advisors
Co-Founder & CEO
Anthony Johnson is an experienced executive with a strong track record of leadership across the healthcare sector. His experience has covered a multitude of areas MORE
Head of Research & Development
Jean-Michel is an accomplished drug development executive. Starting as a director of clinical pharmacology at Aventis (and predecessor companies), and he then became the Head MORE
Stephen Chang Ph.D.
Senior Vice-President Research
Dr. Stephen Chang serves on the Scientific Advisory Board or Board of Directors for GT Biopharma, Orphesus Therapeutics, Cloak Therapeutics, Aegis Therapeutics and Legacy Therapeutics. MORE
News & Updates
Kodikaz was awarded a Seed grant from Biolocity. The competitive grant process was awarded to help the company further the product development of its targeted cell specific Zip-Code technology for clinical applications in Multiple Myeloma. The grant is for 6 months of work commencing March 2020.